Brand Name
Cerezyme
Generic Name
Imiglucerase
View Brand Information FDA approval date: May 23, 1994
Classification: Hydrolytic Lysosomal Glucocerebroside-specific Enzyme
Form: Injection
What is Cerezyme (Imiglucerase)?
Cerezyme is indicated for treatment of adults and pediatric patients 2 years of age and older with Type 1 Gaucher disease that results in one or more of the following conditions: anemia thrombocytopenia bone disease hepatomegaly or splenomegaly Cerezyme is a hydrolytic lysosomal glucocerebrosidase-specific enzyme indicated for treatment of adults and pediatric patients 2 years of age and older with Type 1 Gaucher disease that results in one or more of the following conditions: anemia, thrombocytopenia, bone disease, hepatomegaly or splenomegaly.
Approved To Treat
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
Gaucher Disease Registry Protocol
Summary: The ICGG Gaucher Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Gaucher disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The objectives of the Reg...